Perioperative mepolizumab in aspirin-exacerbated respiratory disease does not prevent nasal polyp regrowth

Aspirin-exacerbated respiratory disease (AERD) is defined by the triad of asthma, chronic rhinosinusitis with nasal polyps (CRSwNP), and respiratory reactions to medications that inhibit cyclooxygenase-1. Of these elements, patients with AERD cite CRSwNP symptoms as the most impactful on quality of life1. Patients with AERD are less likely to respond to first-line therapy with intranasal glucocorticoids and more likely to require multiple functional endoscopic sinus surgeries (FESS) compared to aspirin-tolerant CRSwNP2.

Source: Annals of Allergy, Asthma and Immunology - June 17, 2023 Category: Allergy & Immunology Authors: Andrew D. Supron, Regan W. Bergmark, Rachel E. Roditi, Kathleen M. Buchheit Source Type: research